Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of intrapleural recombinant modified human tumor necrosis factor plus sintilimab and chemotherapy for first-line driver-negative non-squamous NSCLC with malignant pleural effusion
ChiCTR2300077573Phase 2Not yet recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Nov 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rmhTNF-NC and sintilimab in non-small cell lung cancer (NSCLC) and malignant pleural effusion (MPE), sponsored by Shandong Cancer Hospital. Primary endpoint: objective response rate. Planned start Nov 2023; status: not yet recruiting.
02
Drugs
rmhTNF-NCsintilimab
03
Conditions
non-small cell lung cancer (NSCLC)malignant pleural effusion (MPE)
Beyond the preview
Go deeper on ChiCTR2300077573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300077573.